About Eslicarbazepine Acetate API
Therapeutic CategoryCentral Nervous System (CNS)

CAS Number
236395-14-5
API Technology
Synthetic
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, EUDMF
Mechanism of Action
APTIOM is extensively converted to eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels.
Indication
APTIOM is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Related APIs
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
FAQs
Treats partial-onset seizures in epilepsy
Monitor for suicidal thoughts
Avoid abrupt discontinuation
Watch for serious skin reactions and hyponatremia
Reduces seizure frequency
Effective as monotherapy or adjunct therapy
Stabilizes neuronal activity
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.